DOI QR코드

DOI QR Code

액토스정®(피오글리타존 30 mg)에 대한 염산피오글리타존정의 생물학적동등성

Bioequivalence of pioglitazone tablet to Actos® tablet (Pioglitazone 30 mg)

  • 투고 : 2009.01.08
  • 심사 : 2009.02.03
  • 발행 : 2009.02.25

초록

다케다약품공업주식회사의 "액토스정$^{(R)}$ 30 mg"을 대조약으로 하고 보령제약주식회사의 "염산피오글리타존정 30 mg"을 시험약으로 하여, $2{\times}2$ 교차시험법에 따라 지원자 28 명을 대상으로 생물학적동등성시험을 실시하였다. 이를 위하여 피오글리타존 30 mg을 각 지원자에게 경구 투여한 후, 0-36 시간 동안 채혈한 혈장 시료를 확보하였다. 혈장 중 피오글리타존을 분석하기 위하여, LC-MS/MS 분석법을 확립하였으며 분석결과의 신뢰성을 높이기 위하여 분석법 검증을 수행하였다. 그 결과, 5-2000 ng/mL의 농도범위에서 우수한 직선성을 나타내었으며, 생물학적동등성시험에 이용될 수 있는 충분한 감도와 특이성, 정밀성 및 정확성을 확인하였다. 각 피험자들의 혈중 약물농도 데이터로부터 구한 혈중약물농도-시간곡선하면적($AUC_t$)과 최고혈중농도($C_{max}$) 등의 약물속도론적 파라미터에 대해 통계학적으로 고찰한 결과, 판정기준을 만족 시켰으며, 따라서 두 제제는 생물학적으로 동등한 것으로 평가하였다.

The bioequivalence of two pioglitazone tablets, Actos$^{(R)}$ tablet (Takeda Chemical Industries, reference drug) and Pioglitazone tablet (Boryung Company, test drug) was evaluated according to the guidelines of Korea Food and Drug Administration. Twenty-eight healthy male Korean volunteers received each medicine (pioglitazone dose of 30 mg) in a $2{\times}2$ crossover study with one week washout interval. After drug administration, blood samples were collected at specific time intervals from 0-36 hours. The plasma concentrations of pioglitazone were determined by high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). The total chromatographic run time was 5 min and calibration curves were linear over the concentration range of 5-2000 ng/mL for pioglitazone. The method was validated for selectivity, sensitivity, linearity, accuracy and precision. The pharmacokinetic parameters were determined from the plasma concentration-time profiles of both formulations. The primary calculated pharmacokinetic parameters were compared statistically to evaluate bioequivalence between the two preparations. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{max}$ ratio for Pioglitazone tablet and Actos$^{(R)}$ tablet were log0.9422~log1.1040 and log0.9200~log1.1556, respectively. Based on the statistical considerations, we can conclude that the test drug, Pioglitazone tablet was bioequivalent to the reference drug, Actos$^{(R)}$ tablet.

키워드

참고문헌

  1. J. Waugh, G. M. Keating, G. L. Plosker, S. Easthope and D. M. Robinson, Drugs, 66, 85-109(2006) https://doi.org/10.2165/00003495-200666010-00005
  2. Takeda Pharmaceutical Company Limited, Actos$^{\circledR}$ (pioglitazone hydrochloride) Full Prescribing Information, Osaka, Japan, 2004, http://www.actos.com/pi.pdf
  3. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson and S. A. Kliewer, J. Biol. Chem., 270, 12953-12956(1995) https://doi.org/10.1074/jbc.270.22.12953
  4. J. Sakamoto, H. Kimura, S. Moriyama, H. Odaka, Y. Momose, Y. Sugiyama and H. Sawada, Biochem. Biophys. Res. Commun., 278, 704-711 (2000) https://doi.org/10.1006/bbrc.2000.3868
  5. J. Chilcott, MSc, P. Tappenden, M. L. Jones, M. A. DPhU and J. P. Wight, Clin. Therapeut., 23, 1792 (2001)
  6. P. Sripalakit, P. Neamhom and A. Saraphanchotiwitthaya, J. Chromatogr. B, 843, 164-169(2006) https://doi.org/10.1016/j.jchromb.2006.05.032
  7. S. Wittayalertpanya, S. Chompootaweep and N. P. Thaworn, J. Med. Assoc. Thailand, 89, 2116-2122(2006)
  8. 식품의약품안전청 고시 제 2007-65호, 생물학적동등성시험기준 (2007. 09. 20)
  9. Y. J. Xue, K. C. Turner, J. B. Meeker, J. Pursley, M. Arnold and S. Unger, J. Chromatogr. B, 795, 215-226(2003) https://doi.org/10.1016/S1570-0232(03)00575-0
  10. International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Validation of analytical procedures, ICH-Q2A, Geneva, 1995
  11. FDA Guidelines, Bioequivalence Food and Drug Administration, Division of Bioequivalence, Office of Generic Drugs, Rockville, MD USA, 1992